Ergomed Share Discussion Threads

[maddox] 29/1/2023 11:03

Richard Barfield has been extremely impressive so very grateful for his contribution to the transformation of ERGO. He will be a difficult act to follow. However, the strategy is set and the execution going exceedingly well so his contribution will be sustained.

He has a c. 1m options on shares which is equivalent to about 2% of ERGO, so we'll have to see what he does with these. Hopefully he'll retain a sizeable holding in ERGO and an informal, if not formal, advisory role in future.

Apart from that I like to express my thanks as a shareholder and wish him a very long and very, very happy retirement. If you share my sentiments please give this post a thumbs-up.

Cheers Maddox

[mfhmfh] 27/1/2023 10:19

better he retired then jumped ship to another company. IMHO.

[piedro] 26/1/2023 16:00

"Richard Barfield retiring is a big negative ..."

LOL, no doubt conspiracy theories abound

"he sold a large part of his shareholding last year - I took his cue and sold out then"

So what?. He cashed in 125,000 10p options and has plenty more

[qvg] 26/1/2023 15:11

RB's retirement a very big negative sign. he sold a large part of his shareholding last year - I took his cue and sold out then

[ihatemms] 26/1/2023 12:28

Richard Barfield retiring is a big negative on the stock unfortunately. In short he transformed his previous company and then Ergomed - check the share price after he was appointed .The retirement expectation was on the wall when the deputy CFO was appointed. I sold half before the announcement and the other half yesterday.

[fegger] 26/1/2023 10:56

Positive trading update. https://uk.advfn.com/stock-market/london/ergomed-ERGO/share-news/Ergomed-plc-Ergomed-2022-Trading-Update/90051338?xref=newsalert

But no move in share price. Likely due to the still high PE ratio in an era where PEs have reduced a lot.

[piedro] 14/10/2022 15:34

Octopus holdings {from my records}

[piedro] 10/10/2022 11:06

PrimeVigilance@PrimeVigilance
EVENT – Greetings from Tokyo! We are so pleased to be a first-time exhibitor
at the DIA Japan Annual Meeting.
If you are attending, look up Booth #19 and stop by to meet our team from our
regional hub in Tokyo.

[phillis] 27/9/2022 16:06

It is a service business
Productivity improvements are probably limited

[piedro] 27/9/2022 12:19

Updated chart ...



- that is what I wanted to see: cost growth moderated

[ihatemms] 27/9/2022 09:46

Another very impressive web-cast today.

[piedro] 26/7/2022 11:32

Ergomed cheers 'very strong' performance in first half of 2022

hTTps://www.youtube.com/watch?v=FpZVQuZlTUU

[adorling] 26/7/2022 09:54

Excellent update for interims and H2 outlook particularly order book. glad I topped up recently.

[piedro] 26/7/2022 09:47

Business as usual update,
but can they keep costs under control?

[mfhmfh] 25/7/2022 11:22

let's see what tomorrow brings

[capitalist] 10/6/2022 07:18

Update looks good to me.

[phillis] 29/3/2022 10:22

Includes £3m contingent earn out deemed employment cost

[ihatemms] 29/3/2022 07:08

Super results yet again - above expectations. This stock deserves a premium rating.

[km18] 17/2/2022 17:27

...from last year...

Company overview:
Founded in 1997, Ergomed plc is a specialist services provider for the pharmaceutical industries, covering all phases of clinical development, post-approval pharmacovigilance and medical information. The company operates in more than 100 countries through its Pharmacovigilance and Clinical research Outsourcing service lines. The company has made several acquisitions over the past 5 years.
Last three years’ performance is categorized by steady growth in Revenue, gross Profit and adjusted EBITDA and order book growth in 2020 of 55.5%. Acquisition in 2020 was in the USA with ambition to increase market presence for both business lines. Revenue in USA is currently accounting for around 54%, compared to UK’s 14% and EU area 27%. Latest update from the company shows strong trade with 38% growth in revenue in the first half of the year bringing the interim figure to £56m. CRO division generated a staggering 90.7%. Healthy balance sheet and prospects for growth are firmly supported by increase in cash balance to £24.6m and growth in order book at 18% since 01/01/2021....from WealthOracleAM

https://wealthoracle.co.uk/detailed-result-full/ERGO/46